Skip to Content
Merck
CN

ADAR1-mediated regulation of melanoma invasion.

Nature communications (2018-06-02)
Yael Nemlich, Erez Nissim Baruch, Michal Judith Besser, Einav Shoshan, Menashe Bar-Eli, Liat Anafi, Iris Barshack, Jacob Schachter, Rona Ortenberg, Gal Markel
ABSTRACT

Melanoma cells use different migratory strategies to exit the primary tumor mass and invade surrounding and subsequently distant tissues. We reported previously that ADAR1 expression is downregulated in metastatic melanoma, thereby facilitating proliferation. Here we show that ADAR1 silencing enhances melanoma cell invasiveness and ITGB3 expression. The enhanced invasion is reversed when ITGB3 is blocked with antibodies. Re-expression of wild-type or catalytically inactive ADAR1 establishes this mechanism as independent of RNA editing. We demonstrate that ADAR1 controls ITGB3 expression both at the post-transcriptional and transcriptional levels, via miR-22 and PAX6 transcription factor, respectively. These are proven here as direct regulators of ITGB3 expression. miR-22 expression is controlled by ADAR1 via FOXD1 transcription factor. Clinical relevance is demonstrated in patient-paired progression tissue microarray using immunohistochemistry. The novel ADAR1-dependent and RNA-editing-independent regulation of invasion, mediated by ITGB3, strongly points to a central involvement of ADAR1 in cancer progression and metastasis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-ADAR1 antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody
Sigma-Aldrich
Anti-Integrin β3 Antibody, clone 25E11, azide free, clone 25E11, Chemicon®, from mouse
Sigma-Aldrich
Anti-Integrin beta-3 Antibody, from rabbit, purified by affinity chromatography